JP2024518410A - 重症筋無力症を治療するための抗cd19抗体の使用 - Google Patents

重症筋無力症を治療するための抗cd19抗体の使用 Download PDF

Info

Publication number
JP2024518410A
JP2024518410A JP2023568333A JP2023568333A JP2024518410A JP 2024518410 A JP2024518410 A JP 2024518410A JP 2023568333 A JP2023568333 A JP 2023568333A JP 2023568333 A JP2023568333 A JP 2023568333A JP 2024518410 A JP2024518410 A JP 2024518410A
Authority
JP
Japan
Prior art keywords
subject
dose
antibody
administration
score
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023568333A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024518410A5 (cg-RX-API-DMAC7.html
Inventor
エリエゼル カッツ
ジョン エヌ. ラッチフォード
リロン アブシラ
Original Assignee
ビエラ バイオ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ビエラ バイオ インコーポレイテッド filed Critical ビエラ バイオ インコーポレイテッド
Publication of JP2024518410A publication Critical patent/JP2024518410A/ja
Publication of JP2024518410A5 publication Critical patent/JP2024518410A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023568333A 2021-05-07 2022-05-06 重症筋無力症を治療するための抗cd19抗体の使用 Pending JP2024518410A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163185613P 2021-05-07 2021-05-07
US63/185,613 2021-05-07
US202263303655P 2022-01-27 2022-01-27
US63/303,655 2022-01-27
PCT/US2022/028063 WO2022236047A1 (en) 2021-05-07 2022-05-06 Use of an anti-cd19 antibody to treat myasthenia gravis

Publications (2)

Publication Number Publication Date
JP2024518410A true JP2024518410A (ja) 2024-05-01
JP2024518410A5 JP2024518410A5 (cg-RX-API-DMAC7.html) 2025-05-13

Family

ID=81846343

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023568333A Pending JP2024518410A (ja) 2021-05-07 2022-05-06 重症筋無力症を治療するための抗cd19抗体の使用

Country Status (10)

Country Link
US (1) US20240270842A1 (cg-RX-API-DMAC7.html)
EP (1) EP4333987A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024518410A (cg-RX-API-DMAC7.html)
KR (1) KR20240004367A (cg-RX-API-DMAC7.html)
AU (1) AU2022270697A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023022133A2 (cg-RX-API-DMAC7.html)
CA (1) CA3217586A1 (cg-RX-API-DMAC7.html)
IL (1) IL308296A (cg-RX-API-DMAC7.html)
MX (1) MX2023012703A (cg-RX-API-DMAC7.html)
WO (1) WO2022236047A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024210360A1 (en) * 2023-01-20 2025-06-26 Viela Bio, Inc. Anti-cd19 binding agents for the treatment and prevention of immune mediated necrotizing myopathy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008031056A2 (en) * 2006-09-08 2008-03-13 Medimmune, Llc Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
WO2009052431A2 (en) * 2007-10-19 2009-04-23 Seattle Genetics, Inc. Cd19 binding agents and uses thereof
WO2010095031A2 (en) * 2009-02-23 2010-08-26 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
WO2020219743A2 (en) * 2019-04-24 2020-10-29 Viela Bio, Inc. Use of an anti-cd19 antibody to treat autoimmune disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
AU3272695A (en) 1994-08-12 1996-03-07 Immunomedics Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
AU2001268427B2 (en) 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
PL403488A1 (pl) 2001-05-24 2013-07-08 Zymogenetics, Inc. Zastosowanie bialka fuzyjnego TACI-immunoglobulina, bialko fuzyjne, czasteczka kwasu nukleinowego kodujaca bialko fuzyjne, kompozycja farmaceutyczna i sposób wytwarzania bialka fuzyjnego TACI-immunoglobulina
KR100944575B1 (ko) 2002-10-17 2010-02-25 젠맵 에이/에스 Cd20에 대한 인간 모노클로날 항체
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
ES2537738T3 (es) 2003-06-05 2015-06-11 Genentech, Inc. Terapia de combinación para trastornos de células B
DOP2006000029A (es) 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
EP3157553A4 (en) 2014-06-16 2018-02-28 Xencor, Inc. Treatment for chronic lymphocytic leukemia (cll)
WO2017148880A1 (en) 2016-03-01 2017-09-08 F. Hoffmann-La Roche Ag Obinutuzumab variants having altered cell death induction

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008031056A2 (en) * 2006-09-08 2008-03-13 Medimmune, Llc Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
WO2009052431A2 (en) * 2007-10-19 2009-04-23 Seattle Genetics, Inc. Cd19 binding agents and uses thereof
WO2010095031A2 (en) * 2009-02-23 2010-08-26 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
WO2020219743A2 (en) * 2019-04-24 2020-10-29 Viela Bio, Inc. Use of an anti-cd19 antibody to treat autoimmune disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NAT REV, vol. 15, JPN6026028042, 2019, pages 113 - 124, ISSN: 0005901479 *

Also Published As

Publication number Publication date
US20240270842A1 (en) 2024-08-15
KR20240004367A (ko) 2024-01-11
AU2022270697A1 (en) 2023-10-19
MX2023012703A (es) 2023-11-21
WO2022236047A9 (en) 2023-09-21
BR112023022133A2 (pt) 2023-12-26
IL308296A (en) 2024-01-01
CA3217586A1 (en) 2022-11-10
WO2022236047A1 (en) 2022-11-10
EP4333987A1 (en) 2024-03-13

Similar Documents

Publication Publication Date Title
WO2023095852A1 (en) Treatment of a demyelinating disease of the central nervous system (cns) with satralizumab
JP7779738B2 (ja) 自己免疫疾患を治療するための抗cd19抗体の使用
WO2022223714A1 (en) Anti-ifnar1 dosing regime for subcutaneous injection
TW201521757A (zh) 先後通過利妥昔單抗(rituximab)誘導治療及格拉默醋酸鹽(glatiramer acetate)治療
JP2025092553A (ja) 全身型重症筋無力症を治療するための抗c5抗体の投与量及び投与
TW202133877A (zh) 全身性紅斑狼瘡中之i型干擾素抑制
TW202539734A (zh) 使用白細胞介素-17(il-17)拮抗劑治療自體免疫性疾病之方法
US20240270842A1 (en) Use of an anti-cd19 antibody to treat myasthenia gravis
JP2022501378A (ja) 視神経脊髄炎の処置のためのエクリズマブ
CN116322765A (zh) 用于用奥瑞珠单抗治疗多发性硬化症的方法
TW202330022A (zh) 抗cd19抗體治療重症肌無力之用途
EA052907B1 (ru) Применение антитела к cd19 для лечения миастении гравис
JP2024526742A (ja) 重症筋無力症の治療のための抗c5抗体の投与量及び投与
JP2024517796A (ja) 抗baffr抗体を使用するループス腎炎の治療
KR20250135238A (ko) 면역 매개 괴사성 근병증의 치료 및 예방을 위한 항-cd19 결합제
RU2852738C1 (ru) Способы лечения аутоиммунных заболеваний с применением антагонистов интерлейкина-17 (il-17)
HK40107811A (en) Treatment of a demyelinating disease of the central nervous system (cns) with satralizumab
CN119630422A (zh) 使用白细胞介素-17(il-17)拮抗剂治疗巨细胞动脉炎的方法
CN117157099A (zh) 用于皮下注射的抗ifnar1给药方案
HK40011843A (en) A pharmaceutical composition for averting opioid addiction

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250501

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250501

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260629

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260706

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260806